The Histone methyltransferase inhibitor A-366 uncovers a role for G9a/GLP in the epigenetics of leukemia

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Pappano, William N ^a   Guo, Jun ^a   He, Yupeng ^a   Ferguson, Debra ^a   Jagadeeswaran, Sujatha ^a   Osterling, Donald J ^a   Gao, Wenqing ^a   Spence, Julie K ^a   Pliushchev, Marina ^a   Sweis, Ramzi F ^a   Buchanan, Fritz G ^a   Michaelides, Michael R ^a   Shoemaker, Alexander R ^a   Tse, Chris ^a   Chiang, Gary G ^a  

^a ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOHEXYL N (1 ISOPROPYL 4 PIPERIDINYL) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY] 4 QUINAZOLINAMINE; A 366; HISTONE LYSINE METHYLTRANSFERASE; HISTONE LYSINE METHYLTRANSFERASE G9A; HISTONE LYSINE METHYLTRANSFERASE GLP; HISTONE METHYLTRANSFERASE INHIBITOR; METHYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; 5'-METHOXY-6'-(3-(PYRROLIDIN-1-YL)PROPOXY)SPIRO(CYCLOBUTANE-1,3'-INDOL)-2'-AMINE; ENZYME INHIBITOR; G9A PROTEIN, MOUSE; INDOLE DERIVATIVE; SPIRO COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CELL DIFFERENTIATION; CELL GROWTH; CELL STRUCTURE; CONTROLLED STUDY; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; GENETIC EPIGENESIS; GENETICS; MCF-7 CELL LINE; PATHOLOGY; SCID MOUSE; XENOGRAFT;

ANIMALS; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FEMALE; HETEROGRAFTS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; INDOLES; LEUKEMIA; MCF-7 CELLS; MICE; MICE, SCID; SPIRO COMPOUNDS;

EID: 84940093455     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131716     Document Type: Article

References (31)

1. Helin K, Dhanak D. Chromatin proteins and modifications as drug targets. Nature. 2013;502(7472):480-8. doi: 10.1038/nature12751 PMID: 24153301.
2. Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nature reviews Drug discovery. 2009;8(9):724-32. doi: 10.1038/nrd2974 PMID: 19721445.
3. Jenuwein T. The epigenetic magic of histone lysine methylation. The FEBS journal. 2006;273(14):3121-35. doi: 10.1111/j.1742-4658.2006.05343.x PMID: 16857008.
4. Varier RA, Timmers HT. Histone lysine methylation and demethylation pathways in cancer. Biochim Biophys Acta. 2011;1815(1):75-89. doi: 10.1016/j.bbcan. 2010.10.002 PMID: 20951770.
5. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nature reviews Drug discovery. 2012;11(5):384-400. doi: 10.1038/nrd3674 PMID: 22498752.
6. Portela A, Esteller M. Epigenetic modifications and human disease. Nature biotechnology. 2010;28(10):1057-68. doi: 10.1038/nbt.1685 PMID: 20944598.
7. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492(7427):108-12. doi: 10.1038/nature11606 PMID: 23051747.
8. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20(1):53-65. doi: 10.1016/j.ccr.2011.06.009 PMID: 21741596.
9. Tachibana M, Ueda J, Fukuda M, Takeda N, Ohta T, Iwanari H, et al. Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9. Genes & development. 2005;19(7):815-26. doi: 10.1101/gad.1284005 PMID: 15774718; PubMed Central PMCID: PMC1074319.
10. Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M, et al. G9ahistone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryo-genesis. Genes & development. 2002;16(14):1779-91. doi: 10.1101/gad.989402 PMID: 12130538; PubMed Central PMCID: PMC186403.
11. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129(4):823-37. doi: 10.1016/j.cell.2007.05.009 PMID: 17512414.
12. Dong KB, Maksakova IA, Mohn F, Leung D, Appanah R, Lee S, et al. DNA methylation in ES cells requires the lysine methyltransferase G9a but not its catalytic activity. EMBO J. 2008;27(20):2691-701. doi: 10.1038/emboj.2008.193 PMID: 18818693; PubMed Central PMCID: PMC2572176.
13. Huang J, Dorsey J, Chuikov S, Perez-Burgos L, Zhang X, Jenuwein T, et al. G9aand Glp methylate lysine 373 in the tumor suppressor p53. The Journal of biological chemistry. 2010;285(13):9636-41. doi: 10.1074/jbc. M109.062588 PMID: 20118233; PubMed Central PMCID: PMC2843213.
14. Kondo Y, Shen L, Ahmed S, Boumber Y, Sekido Y, Haddad BR, et al. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One. 2008;3(4):e2037. doi: 10.1371/journal.pone.0002037 PMID: 18446223; PubMed Central PMCID: PMC2323574.
15. Kondo Y, Shen L, Suzuki S, Kurokawa T, Masuko K, Tanaka Y, et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatology research: the official journal of the Japan Society of Hepatology. 2007;37(11):974-83. doi: 10.1111/j. 1872-034X.2007.00141.x PMID: 17584191.
16. Watanabe H, Soejima K, Yasuda H, Kawada I, Nakachi I, Yoda S, et al. Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer cell international. 2008;8:15. doi: 10.1186/1475-2867-8-15 PMID: 18980680; PubMed Central PMCID: PMC2584620.
17. Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G, et al. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res. 2010;70(20):7830-40. doi: 10.1158/0008-5472. CAN-10-0833 PMID: 20940408.
18. Kubicek S, O'Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Molecular cell. 2007;25(3):473-81. doi: 10.1016/j.molcel.2007.01.017 PMID: 17289593.
19. Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V, et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nature chemical biology. 2011;7(8):566-74. doi: 10.1038/nchembio.599 PMID: 21743462; PubMed Central PMCID: PMC3184254.
20. Sweis RF, Pliushchev M, Brown PJ, Guo J, Li F, Maag D, et al. Discovery and Development of Potent and Selective Inhibitors of Histone Methyltransferase G9a. ACS Med Chem Lett. 2014;5(2):205-9. doi: 10.1021/ml400496h PMID: 24900801
21. Pappano WN, Jung PM, Meulbroek JA, Wang YC, Hubbard RD, Zhang Q, et al. Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605. BMC cancer. 2009;9:314. doi: 10.1186/1471-2407-9-314 PMID: 19732452; PubMed Central PMCID: PMC2749869.
22. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood. 2009;113(16):3655-65. doi: 10.1182/blood-2009-01-198911 PMID: 19221035; PubMed Central PMCID: PMC2943835.
23. Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene. 2001;20(49):7140-5. doi: 10.1038/sj.onc.1204763 PMID: 11704842.
24. Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005;11(10):3604-8. doi: 10.1158/1078-0432. CCR-04-2135 PMID: 15897554.
25. Lehnertz B, Northrop JP, Antignano F, Burrows K, Hadidi S, Mullaly SC, et al. Activating and inhibitory functions for the histone lysine methyltransferase G9a in T helper cell differentiation and function. The Journal of experimental medicine. 2010;207(5):915-22. doi: 10.1084/jem.20100363 PMID: 20421388; PubMed Central PMCID: PMC2867284.
26. Lehnertz B, Pabst C, Su L, Miller M, Liu F, Yi L, et al. The methyltransferase G9a regulates HoxA9-dependent transcription in AML. Genes & development. 2014;28(4):317-27. doi: 10.1101/gad.236794. 113 PMID: 24532712; PubMed Central PMCID: PMC3937511.
27. Schaefer A, Sampath SC, Intrator A, Min A, Gertler TS, Surmeier DJ, et al. Control of cognition and adaptive behavior by the GLP/G9aepigenetic suppressor complex. Neuron. 2009;64(5):678-91. doi: 10.1016/j.neuron. 2009.11.019 PMID: 20005824; PubMed Central PMCID: PMC2814156.
28. Maze I, Covington HE 3rd, Dietz DM, La Plant Q, Renthal W, Russo SJ, et al. Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science. 2010;327(5962):213-6. doi: 10. 1126/science.1179438 PMID: 20056891; PubMed Central PMCID: PMC2820240.
29. Imai K, Togami H, Okamoto T. Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. The Journal of biological chemistry. 2010;285(22):16538-45. doi: 10.1074/jbc. M110.103531 PMID: 20335163; PubMed Central PMCID: PMC2878073.
30. Artal-Martinezde Narvajas A, Gomez TS, Zhang JS, Mann AO, Taoda Y, Gorman JA, et al. Epigenetic regulation of autophagy by the methyltransferase G9a. Mol Cell Biol. 2013;33(20):3983-93. doi: 10. 1128/MCB.00813-13 PMID: 23918802; PubMed Central PMCID: PMC3811684.
31. Liu F, Barsyte-Lovejoy D, Li F, Xiong Y, Korboukh V, Huang XP, et al. Discovery of an in vivo chemical probe of the lysine methyltransferases G9aandGLP. Journal of medicinal chemistry. 2013;56(21):8931-42. doi: 10.1021/jm401480r PMID: 24102134; PubMed Central PMCID: PMC3880643.